ROCKVILLE, Md., Feb. 7, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 15 th Annual BIO CEO & Investor Conference 2013 in New York City on Tuesday, February 12, at 9:30 a.m. EST, in the Duke of Windsor Room at The Waldorf Astoria Hotel. Garr will present an update on the company's NSI-566 cell therapy clinical trials, including the FDA-approved chronic spinal cord injury Phase I; ALS Phase II; and the ischemic stroke Phase I/II in Beijing, which the company expects to initiate this month. Additionally, Garr will provide an update on Neuralstem's neurogenic small molecule NSI-189 Phase Ib trial in major depressive disorder.
The webcast will be available in real-time at http://www.veracast.com/webcasts/bio/ceoinvestor2013/22206293.cfm and, again, beginning one hour after the conclusion of the live event, and archived for 90 days. The webcast link will also be posted on the Investor Center home page on Neuralstem's website: www.neuralstem.com.
The BIO CEO & Investor Conference 2013 will be held in New York City, February 11-12. For more information, see: http://www.bio.org/events/conferences/bio-ceo-investor-conference.Neuralstem's President and CEO Richard Garr is also scheduled to serve on the panel, "Treating the Aging Patient with Stem Cells," at the 8 th Annual New York Stem Cell Summit '13, also in New York City, on Tuesday, February 19, beginning at 11:05 a.m. EST. For more information, see: http://www.stemcellsummit.com/newyork/. Garr is also scheduled to present at the 7 th Annual BIO-Europe Spring Conference 2013, CNS/Neurology track, on Tuesday, March 12, at 9:30 a.m., in Barcelona. For more information, see: http://www.ebdgroup.com/bes/index.php. About Neuralstem Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed dosing of the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, in August 2012; the trial ends six months after that last surgery. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy. In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013. Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV